Treatment response
There were no discrepancies in response type assessment between the two independent pulmonologists, so consensus was reached independently in all patients (details can be found in the supplementary Table The evolution of FVC and DLCO during the course of the study is given in Figs. Relative FVC change (%) 6 to 9 months prior to rituximab therapy and 6 months after (Relative DLCO change (%) 6 to 9 months prior to rituximab therapy and 6 months after (